Ergomed Clinical Research India Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 16-06-2024
- Paid Up Capital ₹ 0.10 M
as on 16-06-2024
- Company Age 11 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 127.61%
(FY 2023)
- Profit 102.80%
(FY 2023)
- Ebitda 122.84%
(FY 2023)
- Net Worth 95.18%
(FY 2023)
- Total Assets 156.66%
(FY 2023)
About Ergomed Clinical Research India
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Salem Araya, Ridhima Arora, and Dragan Kovacevic serve as directors at the Company.
- CIN/LLPIN
U73200MH2013PTC249804
- Company No.
249804
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Nov 2013
- Date of AGM
15 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Ergomed Clinical Research India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dragan Kovacevic  | Director | 31-Aug-2018 | Current |
Salem Araya  | Director | 31-Aug-2022 | Current |
Ridhima Arora  | Director | 28-Mar-2022 | Current |
Financial Performance of Ergomed Clinical Research India.
Ergomed Clinical Research India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 127.61% increase. The company also saw a substantial improvement in profitability, with a 102.8% increase in profit. The company's net worth Soared by an impressive increase of 95.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ergomed Clinical Research India?
In 2023, Ergomed Clinical Research India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Adamas Clinical Quality Consulting Private LimitedActive 11 years 9 monthsDragan Kovacevic is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ergomed Clinical Research India?
Ergomed Clinical Research India has a workforce of 46 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ergomed Clinical Research India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ergomed Clinical Research India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
